Clinical trial for Pancreatic Cancer
Official title Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
ClinicalTrials.gov ID: NCT07562152
What this study is testing
What is Atebimetinib?
This is an investigational oral tablet being studied as a potential treatment for metastatic pancreatic cancer. is designed to block a specific protein called MEK that helps cancer cells grow and divide.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- This study aims to find out if combining atebimetinib with standard chemotherapy is safe and works better than chemotherapy alone.
- Who it's for
- The study is looking for people with metastatic pancreatic adenocarcinoma who have not yet received treatment for this stage.
- What's involved
- Participants will receive either the new drug combination or standard chemotherapy, along with regular medical check-ups and tests to monitor their health.
- Time commitment
- The duration and specific visit schedule are not detailed in the provided text.
- Phase 3: a large, late-stage study
- Which group you join is decided by chance.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Must be ≥18 years of age
- Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- First-line PDAC participants will have received no previous systemic anti-cancer therapy
- Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
You likely can't join if
- Inability to swallow oral medications
- Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
- Participants with only locally advanced disease
- Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
See the full eligibility criteria
- Must be ≥18 years of age
- Metastatic pancreatic adenocarcinoma within 12 weeks prior to screening
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- First-line PDAC participants will have received no previous systemic anti-cancer therapy
- Must have evidence of measurable disease (at least one target lesion) per RECIST v1.1 criteria
- Adequate organ function, hepatic function, coagulation studies and protocol determined clinical laboratory values
- Inability to swallow oral medications
- Participant has squamous, adenosquamous, neuroendocrine (carcinoid, islet cell) or acinar pancreatic carcinoma
- Participants with only locally advanced disease
- Symptomatic, untreated, or actively progressing known central nervous system (CNS) metastases
The study team makes the final eligibility decision.
Where it is enrolling
- Huntsville, Alabama, United States
- Phoenix, Arizona, United States
- Duarte, California, United States
- San Diego, California, United States
- Fort Collins, Colorado, United States
- Lone Tree, Colorado, United States
- Newark, Delaware, United States
- Miami, Florida, United States
- Port Saint Lucie, Florida, United States
- Sarasota, Florida, United States
- St. Petersburg, Florida, United States
- West Palm Beach, Florida, United States
- Atlanta, Georgia, United States
- Arlington Heights, Illinois, United States
- Chicago, Illinois, United States
- Peoria, Illinois, United States
- Fairway, Kansas, United States
- Columbia, Maryland, United States
- Columbia, Missouri, United States
- Omaha, Nebraska, United States
+ 46 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Huntsville, Alabama, United States; Phoenix, Arizona, United States; Duarte, California, United States; San Diego, California, United States; Fort Collins, Colorado, United States; Lone Tree, Colorado, United States and 60 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.